Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Challenges in conducting paediatric trials with off-patent drugs

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hot and Cold Cognitive Disturbances in Parkinson Patients Treated with DBS-STN: A Combined PET and Neuropsychological Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Using soluble urokinase plasminogen activator receptor to stratify patients for medication review in the emergency department

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk factors for fatigue and impaired function eight months after hospital admission with COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Clinical precursors of tics: an EMTICS study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part I: assessment

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Introduction: For more than two decades several initiatives have emerged to increase recruitment of paediatric patients in drug trials. While trials of newly approved drugs have successfully included paediatric patients in their drug development plan, the collection of safety and efficacy data in paediatric patients treated with off-patent drugs poses a major challenge.

Aim: This paper aims to draw attention to problems and solutions across countries in investigator-initiated trials with off-patent drugs and recommendations for improvement.

Discussion: Off-patent drugs represent a particular challenge when they are included in a paediatric trial; these trials are frequently investigator-initiated and have limited resources, off-patent drugs are used in clinical settings and the trial protocol must accommodate e.g. flexible dosing and specimen sampling schedules, off-patent drugs typically exist in few formulations and concentrations which necessitates special or imported formulations. Paediatric trials are in some countries confined by e.g. consent from both parents, regardless of whether the Investigational Medicinal Product (IMP) is a well-known drug or a new experimental drug.

Conclusion: Facilitation of research in off-patent drugs can improve evidence-based and safe treatment for the paediatric population. The following supportive initiatives are recommended: Harmonised regulatory change that improves the consent process in low risk trials to prevent inadequate recruitment. Pharmaceutical expertise should be prioritized to secure the best choice of IMP and supply. Constant focus on flexibility in design to accommodate a multifaceted paediatric population and ensure that trial protocols fit in well with routine clinical care and family life.

Original languageEnglish
Article number100783
JournalContemporary Clinical Trials Communications
Pages (from-to)100783
Publication statusPublished - Sep 2021

    Research areas

  • Clinical trial management, Informed consent, Off-patent drugs, Pediatric clinical trials

ID: 66793851